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Abstract
BACKGROUND: Melanoma is a relatively immunogenic tumor, in which infiltration of melanoma cells by T lympho-
cytes is associated with a better clinical prognosis. We hypothesized that radiation-induced cell death may provide
additional stimulation of an anti-tumor immune response in the setting of anti–CTLA-4 treatment.METHODS: In a pilot
melanoma patient, we prospectively tested this hypothesis. We treated the patient with two cycles of ipilimumab,
followed by stereotactic ablative radiotherapy to two of seven hepatic metastases, and two additional cycles of
ipilimumab. RESULTS: Subsequent positron emission tomography–computed tomography scan indicated that all
metastases, including unirradiated liver lesions and an unirradiated axillary lesion, had completely resolved, consistent
with a complete response by RECIST. CONCLUSION: The use of radiotherapy in combination with targeted immuno-
therapy as a noninvasive in vivo tumor vaccine strategy appears to be a promisingmethod of enhancing the induction
of systemic immune responses and anti-tumor effect.
Translational Oncology (2012) 5, 404–407
Case Report
Here, we report a 57-year-old male patient diagnosed with stage IIA
cutaneous melanoma in November 2007 following biopsy of a
mole on his left posterior arm that revealed melanoma, ulcerated,
with a Breslow thickness of 1.75 mm. He underwent a wide local
excision of his primary lesion and left axillary sentinel node biopsy
in December 2007. Because initial pathologic review was read as
positive for isolated tumor cells in the intracapsular region, he sub-
sequently underwent a completion left axillary dissection in Decem-
ber 2007. Twenty-two axillary lymph nodes were removed and
found to be negative, with one lymph node containing benign cap-
sular nevus cells. He was therefore staged as IIA [per American Joint
Committee on Cancer (AJCC) designation of isolated tumor cells as
node-negative at the time] and did not receive any adjuvant treatment.
The patient remained disease-free until May 2010, when he
developed a new 6- to 8-mm subcutaneous nodule within the mela-
noma scar. Punch biopsy confirmed locally recurrent melanoma
(satellitosis), and he underwent wide local excision of the satellite
metastasis. Pathology revealed residual/recurrent melanoma as well
as a 4-mm microsatellite focus of melanoma within the subcuta-
neous mass, at least 1.5 cm from the main tumor mass. Metastatic
workup with positron emission tomography (PET)–computed
tomography (CT) in June 2010 was negative for distant disease.
He then underwent adjuvant radiotherapy to the site of recurrence
in the left posterior arm, receiving 50.4 Gy in 20 fractions followed
by adjuvant systemic therapy with 1 month of high-dose interferon
completed in August 2010. Repeat PET-CT in January 2011 showed
no evidence of disease.
InMay 2011, the patient noted a new subcutaneous nodule in the left
axillary region, and fine-needle aspiration (FNA) confirmed in-transit
melanoma metastasis. PET-CT in May 2011 revealed two new sub-
centimeter hypermetabolic foci within the liver in addition to the axillary
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metastasis. The left axillary in-transit metastasis was excised inMay 2011,
and CT-guided liver biopsy confirmed metastatic melanoma.
We hypothesized that radiation-induced tumor cell death may
provide further stimulation of an anti-tumor immune response in the
setting of treatment with anti–CTLA-4, and we discussed prospectively
testing this hypothesis by combining these two clinically indicated
and standard-of-care treatments in this patient. The patient agreed
and was started on ipilimumab at 3 mg per kilogram of body weight
every 3 weeks for a total of four doses, with radiation planned to
start after two doses. After receiving the first two doses of ipilimumab,
repeat PET-CT scan in August 2011, performed for radiotherapy
treatment planning purposes, showed progression of liver metastases,
with enlargement of the two previously noted lesions, as well as devel-
opment of five new hypermetabolic foci in the liver. As planned, the
patient received stereotactic radiotherapy to two of the liver metastases
to 54 Gy in three fractions. During administration of cycle 3 of
ipilimumab, he noted the rapid development of a new 5-cm palpable
subcutaneous nodule on his left upper arm, which was confirmed
by fine-needle aspiration to represent another in-transit melanoma
recurrence. He received cycle 4 of ipilimumab in September 2011.
One week later, the patient was admitted to the hospital with nausea
and vomiting and was found to have hypophysitis with an undetectable
cortisol level. He was started on systemic prednisone with immediate
improvement of nausea and vomiting and continued on a slow predni-
sone taper for the next several months.
In December 2011, follow-up PET-CT scan revealed no FDG
uptake in the areas of previously noted liver lesions. There was per-
sistent focal uptake in the left upper arm at the site of the previously
biopsied in-transit melanoma metastasis. The decision was made to
observe the left arm lesion for potential treatment response and not
to pursue surgical excision, as it was unlikely to change his clinical
outcome, and to continue to follow him closely.
The patient was seen again in late February 2012, at which time
his left arm lesion had resolved completely. PET-CT scan at that
time revealed complete resolution of the hypermetabolic lesion in
his left arm and continued complete resolution of all of the hyper-
metabolic liver lesions. He was seen again in August 2012 with
an unremarkable physical exam. PET-CT scan at that time again
showed no evidence of metabolically active malignancy and continued
complete resolution of the previously hypermetabolic left arm lesion and
all of the hypermetabolic liver lesions, at 1-year post-radiation (Figure 1).
The patient continues on a slow steroid taper for resolving hypophysitis.
Discussion
Our patient experienced a systemic complete response to ipilimumab
and local radiotherapy following high-dose radiotherapy to two of
seven metastatic liver lesions after having experienced disease progres-
sion on ipilimumab alone. This is the second report to date of a patient
with metastatic melanoma who had an “abscopal” response to radio-
therapy with ipilimumab and the first report of a patient who achieved
a complete response with this combined treatment [1].
Melanoma is a relatively immunogenic tumor. It is therefore an
immune responsive disease in which infiltration of melanoma lesions
by T lymphocytes is associated with a better clinical prognosis [2].
However, engagement of the T cell antigen receptor by itself is
not sufficient for full T cell activation. A second costimulatory signal
is required for induction of interleukin-2 (IL-2) production, prolifera-
tion, and differentiation to affect function of naïve T cells. Abundant
recent data indicate that the primary source of this costimulation is
Figure 1. PET scans performed before treatment (row 1), at 6 months after treatment (row 2), and at 12 months after treatment
(row 3). Column A (arrow) shows untreated axillary lesion that was no longer apparent at 6 and 12 months after treatment. Column
B (arrow) shows one of two treated hepatic lesions, which showed complete response to treatment at 6 and 12 months after treatment.
Column C (arrows) shows three of five untreated hepatic lesions, which also showed complete response to treatment at 6 and 12 months
after treatment.
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mediated by engagement of CD28 on the T cell surface by members
of the B7 family on the antigen-presenting cell [3]. Expression of B7
has been shown to be limited to specialized cells of the hematopoietic
lineage, including dendritic cells, activated macrophages, and activated
B cells. CTLA-4 is an inhibitory receptor, and inhibiting CTLA-4
thereby stimulates the immune response [4]. CTLA-knockout mice
appear to have spontaneously activated T cells evident at 1 week after
birth, followed by rampant lymphoproliferation and lymphadeno-
pathy. Since thymocyte differentiation and selection proceed normally
in CTLA-4–deficient mice, the rampant T cell expansion indicates that
CTLA-4 plays a critical role in downregulating T cell responses in the
periphery [5]. When used as part of a tumor vaccine strategy, anti–
CTLA-4 antibodies may generate anti-tumor response by two possible
mechanisms: 1)CTLA-4 blockade on tumor-specific effectorT cells, re-
sulting in clonal activation and expansion, and 2) CTLA-4–targeted
depletion of tumor-induced Tregs, which could inhibit immune
responses to tumor antigens [1,6,7]. Radiation also causes a dose-
dependent reduction in Treg proliferation, which parallels the in-
duction in apoptosis in Tregs, and can affect both the phenotype
and suppression function in Tregs [8]. Therefore, the combined
effects of both ipilimumab and radiation on Tregs may be important
determinants of the efficacy of this combination therapy.
The concept of using radiotherapy as a component of a noninvasive
tumor vaccine strategy is a well-established concept, with promising
translational potential as tumor vaccine strategies and immunotherapies
have become available, and is the subject of completed (NCT00185965:
CpG + radiotherapy for lymphoma) and ongoing clinical trials, includ-
ing NCT00861614: ipilimumab + radiotherapy for metastatic prostate
cancer; NCT01421017: Toll-like receptor 7 agonist + radiotherapy for
metastatic breast cancer; NCT01401062: anti–transforming growth
factor–β + radiotherapy for metastatic breast cancer [9]. Preclinical stud-
ies show that local radiotherapy induces tumor cell death and release of
tumor antigens and increases antigen presentation, which can promote
an effective immune response [10,11]. An effective radiotherapy and
immunotherapeutic combination, therefore, would produce an endoge-
nous in situ vaccination against the tumor, which unlike most other
vaccine strategies is entirely noninvasive and does not require intra-
tumoral injections.
The “abscopal” effect, or what could more accurately be termed an
“in vivo vaccination” effect, has previously been demonstrated in pre-
clinical models. Demaria et al. showed decreased pulmonary metas-
tases and improved survival in mice treated with radiotherapy in the
context of CTLA-4 blockade [11]. The effect of dose, fractionation,
and timing of the “abscopal” effect is controversial [10]. Several pre-
clinical studies suggest that hypofractionation is optimal, while other
studies suggest that conventional fractionation is more effective at
promoting an “abscopal” effect [10].
The first clinical report of an “abscopal” effect in a patient receiv-
ing ipilimumab with concurrent radiotherapy was recently reported
by Postow et al., in which they describe a patient with metastatic
melanoma with a paraspinal mass, splenic lesions, and right hilar
lymphadenopathy [1]. This patient was treated palliatively for back
pain caused by the paraspinal mass, to 28.5 Gy in three fractions. She
continued to receive ipilimumab. Five months after radiotherapy, all
lesions were found to have regressed on CT scan, and 10 months
after radiotherapy, lesions were stable with continued presence of
minimal disease.
Our case differs from the one described by Postow et al. in several
ways. First, our patient was asymptomatic at the time of radio-
therapy and was prospectively treated with ipilimumab, not only
because he had progressive metastatic disease, but also because
we hypothesized that it may provide an endogenous vaccination,
which could potentially amplify the systemic anti-melanoma T cell
response in the setting of CTLA-4 blockade. Second, our patient
achieved a complete response with no evidence of disease on CT
or PET scan, although our follow-up interval (12 months) is still rela-
tively short. Third, given the location of his metastatic disease, we
were able to treat with radiotherapy to a higher dose per fraction
(54 Gy in three fractions vs 28.5 Gy in three fractions). This may have
resulted in an increased systemic immune response as suggested in the
preclinical work by Dewan et al., with limited data suggesting a dose-
response relationship [10].
While delayed response to ipilimumab alone has been reported,
the historical overall response rate to ipilimumab in stage IV melanoma
is <10%, with a complete response rate of <2% [7]. The patient’s
left axillary tumor demonstrated likely pseudoprogression, given the
rapid growth followed by rapid resolution, observed in approximately
10% of ipilimumab responses. Finally, the patient also experienced
autoimmune hypophysitis, a well-described adverse effect of ipili-
mumab, and he has responded well to a gradual and ongoing pred-
nisone taper [12].
At the Stanford Cancer Institute, we are currently enrolling patients
on a study in which patients with metastatic melanoma are treated
concurrently with ipilimumab and radiotherapy, with the goal of
enhancing the induction of systemic anti-melanoma immune responses
that will inhibit growth and kill melanoma cells in sites of estab-
lished metastases outside of the radiotherapy field more effectively
than with anti–CTLA-4 alone, with minimal or no additional tox-
icity. The use of targeted immunotherapy in combination with
radiation therapy is becoming an area of increasing interest and
clinical investigation in melanoma. Seung et al. recently reported
results from a phase 1 study combining stereotactic body radiotherapy
and IL-2 in patients with metastatic melanoma or metastatic renal
cell carcinoma and found that 8 of 12 patients had a complete response
(CR) or partial response (PR) by RECIST in unirradiated lesions after
treatment, with a significantly greater frequency of proliferating CD4
cells with an early activated effector memory phenotype in the periph-
eral blood of responders versus nonresponders [13]. This in vivo tumor
vaccine strategy has potential clinical applicability for the treatment of a
variety of tumor types, not only with anti–CTLA-4 or IL-2 but alsowith
other immunotherapies currently in development, such as anti-CD137,
anti–PD-1, and anti–PD-L1.
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